TY - JOUR
T1 - Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men
AU - for the AIDS Malignancy Consortium and Adolescent Medicine Trials Network for HIV/AIDS Interventions
AU - Kahn, Jessica A.
AU - Belzer, Marvin
AU - Chi, Xiaofei
AU - Lee, Jeannette
AU - Gaur, Aditya H.
AU - Mayer, Kenneth
AU - Martinez, Jaime
AU - Futterman, Donna C.
AU - Stier, Elizabeth A.
AU - Paul, Mary E.
AU - Chiao, Elizabeth Y.
AU - Reirden, Daniel
AU - Goldstone, Steven E.
AU - Ortiz Martinez, Ana P.
AU - Cachay, Edward R.
AU - Barroso, Luis F.
AU - Da Costa, Maria
AU - Wilson, Craig M.
AU - Palefsky, Joel M.
N1 - Publisher Copyright:
© 2019 The Authors
PY - 2019/6
Y1 - 2019/6
N2 - The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation.
AB - The aims of this study were to: 1) determine prevalence of anogenital and oral HPV, 2) determine concordance between HPV at anal, perianal, scrotal/penile, and oral sites; and 3) describe factors associated with anogenital HPV types targeted by the 9-valent vaccine. Data were collected from 2012 to 2015 among men who have sex with men 18–26 years of age enrolled in a vaccine trial (N = 145). Penile/scrotal, perianal, anal, and oral samples were tested for 61 HPV types. Logistic regression was used to identify factors associated with types in the 9-valent vaccine. Participants’ mean age was 23.0 years, 55.2% were African-American, and 26.2% were Hispanic; 93% had anal, 40% penile, and 6% oral HPV. Among those with anogenital infection, 18% had HPV16. Concordance was low between anogenital and oral sites. Factors independently associated with a 9-valent vaccine-type HPV were: race (African-American vs. White, OR=2.67, 95% CI=1.11–6.42), current smoking (yes vs. no, OR=2.37, 95% CI=1.03–5.48), and number of recent receptive anal sex partners (2+ vs. 0, OR=3.47, 95% CI=1.16–10.4). Most MSM were not infected with HPV16 or HPV18, suggesting that they may still benefit from HPV vaccination, but anogenital HPV was very common, highlighting the importance of vaccinating men before sexual initiation.
KW - Adolescents
KW - Clinical trials
KW - HIV
KW - Human papillomavirus
KW - Men who have sex with men
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85060700418&partnerID=8YFLogxK
U2 - 10.1016/j.pvr.2019.01.002
DO - 10.1016/j.pvr.2019.01.002
M3 - Article
C2 - 30658128
AN - SCOPUS:85060700418
SN - 2666-6790
VL - 7
SP - 52
EP - 61
JO - Papillomavirus Research
JF - Papillomavirus Research
ER -